Carolyn M. Laurençot

Medicine · Health Sciences

21h-index14.7kcitations35works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(22), Immunotherapy and Immune Responses(17), Virus-based gene therapy research(10), Cancer Immunotherapy and Biomarkers(6), Monoclonal and Polyclonal Antibodies Research(4)

Publications35 total

Data from Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
2023Open Access
Supplementary Data from Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
2023Open Access
Supplementary Data from CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma
2023Open Access
Data from Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
2023Open Access
Supplementary Data from Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
2023Open Access
CCR Translation for This Article from Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
2023Open Access
Data from CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma
2023Open Access
Data from CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma
2023Open Access
Supplementary Data from CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma
2023Open Access
CCR Translation for This Article from Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
2023Open Access
Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial
Nature Medicine·2022· 153 citedOpen Access
Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial
The Lancet HIV·2019· 105 citedOpen Access
Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study
The Lancet·2019· 123 citedOpen Access
Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults
PLoS Medicine·2018· 250 citedOpen Access
Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials
The Lancet·2017· 298 citedOpen Access
Transitioning trauma research
The Journal of Trauma: Injury, Infection, and Critical Care·2016· 1 cited
Randomized Selection Design Trial Evaluating CD8<sup>+</sup>-Enriched Versus Unselected Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy for Patients With Melanoma
Journal of Clinical Oncology·2013· 227 citedOpen Access
Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy
Journal of Immunotherapy·2013· 1.1k citedOpen Access
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells
Blood·2011· 1.4k citedOpen Access
Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
Clinical Cancer Research·2011· 2.1k citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Steven A. Rosenberg(21), Mark E. Dudley(20), Richard M. Sherry(20), Udai S. Kammula(20), Marybeth S. Hughes(20), Nicholas P. Restifo(19), James C. Yang(17), Giao Q. Phan(16), John R. Wunderlich(16), Kathleen E. Morton(14), Deborah E. Citrin(13), Seth M. Steinberg(8), Donald White(8), Paul F. Robbins(7), Donald E. White(6), Russell C. Langan(6), Colin Gross(6), Michelle M. Langhan(5), Marcos Ríos García(5), Peter A. Prieto(5)